BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26582061)

  • 21. Are prediction models for Lynch syndrome valid for probands with endometrial cancer?
    Backes FJ; Hampel H; Backes KA; Vaccarello L; Lewandowski G; Bell JA; Reid GC; Copeland LJ; Fowler JM; Cohn DE
    Fam Cancer; 2009; 8(4):483-7. PubMed ID: 19642020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
    Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
    Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of Lynch syndrome predictive models in a multi-center US referral population.
    Khan O; Blanco A; Conrad P; Gulden C; Moss TZ; Olopade OI; Kupfer SS; Terdiman J
    Am J Gastroenterol; 2011 Oct; 106(10):1822-7; quiz 1828. PubMed ID: 21747416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer.
    Limburg PJ; Harmsen WS; Chen HH; Gallinger S; Haile RW; Baron JA; Casey G; Woods MO; Thibodeau SN; Lindor NM
    Clin Gastroenterol Hepatol; 2011 Jun; 9(6):497-502. PubMed ID: 21056691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome.
    Barrow E; Evans DG; McMahon R; Hill J; Byers R
    J Clin Pathol; 2011 Mar; 64(3):208-14. PubMed ID: 21177748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.
    Kastrinos F; Steyerberg EW; Mercado R; Balmaña J; Holter S; Gallinger S; Siegmund KD; Church JM; Jenkins MA; Lindor NM; Thibodeau SN; Burbidge LA; Wenstrup RJ; Syngal S
    Gastroenterology; 2011 Jan; 140(1):73-81. PubMed ID: 20727894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.
    Goverde A; Spaander MCW; Nieboer D; van den Ouweland AMW; Dinjens WNM; Dubbink HJ; Tops CJ; Ten Broeke SW; Bruno MJ; Hofstra RMW; Steyerberg EW; Wagner A
    Fam Cancer; 2018 Jul; 17(3):361-370. PubMed ID: 28933000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
    Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
    J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for breast cancer as an integral part of Lynch syndrome.
    Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
    Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic mutation risk calculation in Lynch syndrome inheritance: Evaluating the utility of the PREMM
    Aissaoui S; Cartellier C; Seytier T; Giraud S; Calender A
    Bull Cancer; 2017 Mar; 104(3):288-294. PubMed ID: 28038733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.
    Cruz-Correa M; Diaz-Algorri Y; Pérez-Mayoral J; Suleiman-Suleiman W; Gonzalez-Pons Mdel M; Bertrán C; Casellas N; Rodríguez N; Pardo S; Rivera K; Mosquera R; Rodriguez-Quilichini S
    Fam Cancer; 2015 Sep; 14(3):415-25. PubMed ID: 25782445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
    Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
    Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.